clinical trial · NCT06981988
A Study of Linperlisib (YY-20394) in Combination With Rituximab in Patients With Relapsed/Refractory Indolent NHL
Jiangsu HengRui Medicine Co., Ltd.·phase2·not yet recruiting·n = 80
Relapsed/Refractory Indolent NHLLinperlisib ； Rituximab
brief summary
The study is being conducted to evaluate the reasonable dosage, efficacy and safety of Linperlisib in combination with rituximab in subjects with relapsed/refractory (R/R) indolent non-hodgkin lymphoma(NHL) in adults.
started
Jun 1, 2025
primary completion
Aug 1, 2025
completion
Feb 1, 2027
last updated
May 21, 2025
official title
A Study to Explore the Dosage and Efficacy of Linperlisib in Combination With Rituximab and to Validate the Efficacy of Linperlisib in Patients With Relapsed/Refractory Indolent NHL
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol